Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
A paper published in the Journal of Paediatric Gastroenterology and Nutrition explores the role of probiotics in the management of functional gut problems in children. Published in July 2016, the authors conclude that appropriately selected organisms represent a plausible (read effective) intervention for such cases. However, strain specific bacteria were tested and random bacteria are not as effective.1
PURPOSE OF REVIEW:
The purpose of this review was to summarize the evidence regarding probiotics treatment for pediatric IBS.
The overall management of children with IBS should be tailored to the patient’s specific symptoms and identifiable triggers. The four major therapeutic approaches include: pharmacologic, dietary, psychosocial, and complementary/alternative medicine interventions.Although there is limited evidence for efficacy of pharmacological therapies such as antispasmodics and anti-diarrheals, these may have a role in severe cases. A Cochrane review concluded that only weak evidence exists regarding beneficial effects of pharmacological agents in providing relief from symptoms in functional abdominal pain (AP) in children. Role of antibiotics in treatment of children with IBS remains controversial. Various non-pharmacologic treatments are available for pediatric IBS. In a recent systematic review including 24 studies some evidence was found indicating beneficial effects of partially hydrolyzed guar gum (PHGG), cognitive behavioral therapy, hypnotherapy, and probiotics (LGG and VSL#3).Few randomized clinical trials (RCTs) are available in children. A meta-analysis including 9 trials which tested different probiotics as a treatment for Functional Gastrointestinal Disorders (FGIDs) in children and adolescents concluded that Lactobacillus GG, Lactobacillus reuteri DSM 17938 and VSL#3 significantly increased treatment success. We recently showed that, in children with IBS, a mixture of Bifidobacterium infantis M-63®, breve M-16V® and longum BB536® is safe and is associated with better AP control and improved quality of life when compared to placebo.
Probiotics are emerging as new therapeutic tools in FGIDs, due to the recognition of the importance of gut microbiota in influencing brain-gut interactions, and of the role played by intestinal infections in the genesis of AP-FGIDs. Preclinical data suggest that changes in the gut microbiota can affect brain signaling systems related to pain and associated emotional behavior. Therefore, probiotics could play a relevant role in the management of FGIDs, by affecting the gut microbiota or by altering brain function and pain perception centrally.
Giannetti E, Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J Pediatr Gastroenterol Nutr. 2016 Jul;63(1S Suppl 1):S25-S2 View Full Paper
- Does Junk Food increase the risk of Allergies and IBD?
- Clinical evidence for immunomodulatory effects of probiotic bacteria.
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
- The Relationship Between Intestinal Microbiota And The Central Nervous System In Normal Gastrointestinal Function And Disease
- Reading Time: 6 minutes An article in the Brit...
- Reading Time: 5 minutes Published 23rd April 2...
- Reading Time: 6 minutes Published 17th Februar...
- Reading Time: 5 minutes As the UK progresses t...
- Reading Time: 5 minutes As the roll out of vac...
Updates on your email
Don't miss out on our email updates